Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 15Recruiting 9Not yet recruiting 4Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Radiation 4fludarabine 2daratumumab 2Temozolomide 2Specimen Handling 2Radiotherapy 2Irinotecan 2Gemcitabine 2Cytarabine 2Biopsy 2ALT-803 2vocimagene amiretrorepvec 1revumenib 1pembrolizumab 1pelcitoclax 1olutasidenib 1merphos 1irinotecan sucrosofate 1dexamethasone acetate 1dexamethasone 21-phosphate 1dehydroftorafur 1decitabine and cedazuridine drug combination 1carfilzomib 1balstilimab 1auricularum 1X-Rays 1Vorinostat 1Transurethral Resection of Prostate 1Taxes 1Surveys and Questionnaires 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × dexamethasone acetate × 30 days × Clear all
NCT07082270 2026-05-15

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Roswell Park Cancer Institute

Phase 1 Withdrawn
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡